OMBP Financials 07/16/2014 16:40:38 Omni Bio Phar

OMBP Financials 07/16/2014 16:40:38
Omni Bio Pharmaceutical, Inc.
Period Ending Mar 31, 2014 Mar 31, 2013 Mar 31, 2012 Mar 31, 2011
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses
Research and Development 163 297 398 578
Sales, General and Admin. 1,750 5,423 4,237 7,650
Non-Recurring Items - - - -
Other - - - -
Operating Income (1,912) (5,720) (4,635) (8,227)
Income From Continuing Operations
Add'l Income/Expense Items (443) (913) (141) (3)
Earnings Before Interest and Tax (2,407) (7,367) (4,774) (8,225)
Interest Expense 110 88 - -
Earnings Before Tax (2,517) (7,455) (4,774) (8,225)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - (596) (622) -
Net Income Cont. Operations (2,517) (8,051) (5,395) (8,225)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (2,517) (7,455) (5,395) (8,225)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (2,517) (7,455) (5,395) (8,225)